Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease.

Redenšek S, Flisar D, Kojović M, Kramberger MG, Georgiev D, Pirtošek Z, Trošt M, Dolžan V.

J Neuroinflammation. 2019 Feb 27;16(1):50. doi: 10.1186/s12974-019-1439-y.

2.

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease.

Redenšek S, Flisar D, Kojović M, Gregorič Kramberger M, Georgiev D, Pirtošek Z, Trošt M, Dolžan V.

Front Pharmacol. 2019 Jan 28;10:8. doi: 10.3389/fphar.2019.00008. eCollection 2019.

3.

Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease.

Santos-Lobato BL, Borges V, Ferraz HB, Mata IF, Zabetian CP, Tumas V.

Nitric Oxide. 2018 Apr 1;74:86-90. doi: 10.1016/j.niox.2017.06.004. Epub 2017 Jun 8.

PMID:
28602747
4.

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL; PKDS009 Study Group.

CNS Drugs. 2004;18(11):733-46. Erratum in: CNS Drugs. 2005;19(7):633.

PMID:
15330687
5.

Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinson's Disease.

Redenšek S, Jenko Bizjan B, Trošt M, Dolžan V.

Front Genet. 2019 May 16;10:461. doi: 10.3389/fgene.2019.00461. eCollection 2019.

6.
7.

Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.

Lin JJ, Yueh KC, Lin SZ, Harn HJ, Liu JT.

J Neurol Sci. 2007 Jan 31;252(2):130-4. Epub 2006 Dec 28.

PMID:
17196621
8.

Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KD.

Cochrane Database Syst Rev. 2001;(1):CD001519. Review.

PMID:
11279721
9.

Variation of genes involved in oxidative and nitrosative stresses in depression.

Wigner P, Czarny P, Synowiec E, Bijak M, Białek K, Talarowska M, Galecki P, Szemraj J, Sliwinski T.

Eur Psychiatry. 2018 Feb;48:38-48. doi: 10.1016/j.eurpsy.2017.10.012. Epub 2018 Jan 10.

PMID:
29331597
10.

Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects.

Pascale E, Purcaro C, Passarelli E, Guglielmi R, Vestri AR, Passarelli F, Meco G.

J Neurol Sci. 2009 Jan 15;276(1-2):18-21. doi: 10.1016/j.jns.2008.08.017. Epub 2008 Sep 20.

PMID:
18805557
11.

Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update.

Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, Obeso J, Bezard E, Fernagut PO.

Lancet Neurol. 2017 Mar;16(3):238-250. doi: 10.1016/S1474-4422(17)30004-2. Epub 2017 Feb 15. Review.

PMID:
28229895
12.

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.

Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S.

Lancet Neurol. 2014 Aug;13(8):767-76. doi: 10.1016/S1474-4422(14)70148-6. Epub 2014 Jul 6.

PMID:
25008546
13.
14.

Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.

Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, Petyt G, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Azulay JP, Tison F, Destée A, Vidailhet M, Rascol O, Dujardin K, Defebvre L, Bordet R, Sablonnière B, Devos D; Parkgait-II Study Group.

Brain. 2015 May;138(Pt 5):1271-83. doi: 10.1093/brain/awv063. Epub 2015 Mar 23.

15.

Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2000;(3):CD001517. Review. Update in: Cochrane Database Syst Rev. 2001;(1):CD001517.

PMID:
10908504
16.

DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease.

Purcaro C, Vanacore N, Moret F, Di Battista ME, Rubino A, Pierandrei S, Lucarelli M, Meco G, Fattapposta F, Pascale E.

Neurosci Lett. 2019 Jan 18;690:83-88. doi: 10.1016/j.neulet.2018.10.021. Epub 2018 Oct 11.

PMID:
30316985
17.

Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment.

Kaynak D, Kiziltan G, Kaynak H, Benbir G, Uysal O.

Eur J Neurol. 2005 Mar;12(3):199-207.

PMID:
15693809
18.

Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.

Rieck M, Schumacher-Schuh AF, Altmann V, Callegari-Jacques SM, Rieder CRM, Hutz MH.

Pharmacogenomics J. 2018 Jan;18(1):196-200. doi: 10.1038/tpj.2016.79. Epub 2016 Oct 25.

PMID:
27779245
19.

Ropinirole for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2000;(3):CD001516. Review. Update in: Cochrane Database Syst Rev. 2001;(1):CD001516.

PMID:
10908503
20.

[ApoE polymorphisms and dopaminergic replacement therapy in Parkinson's disease].

Cervantes-Arriaga A, Rodríguez-Violante M, González-Latapí P, Dávila-Ortiz de Montellano DJ, Yescas P, Alonso-Vilatela E.

Rev Med Inst Mex Seguro Soc. 2014 Jan-Feb;52(1):14-8. Spanish.

PMID:
24625478

Supplemental Content

Support Center